Who
Anat Cohen-Dayag
Director
Company insider
Files Form 4 as: Director, Compugen; Director, Gamida Cell.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 28 Jan 2022
- Last trade
- 29 Jul 2026
- Last filed
- 30 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jul 2026filed 30 Jul 2026 | CGEN Compugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 29 Jul 2026filed 30 Jul 2026 | CGEN Compugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 8 Feb 2023filed 10 Feb 2023 | Gamida Celloption or derivative | SEC FORM 4 Code A | —56,600 at $0.00 | filing |
| 8 Feb 2023filed 10 Feb 2023 | Gamida Cell | SEC FORM 4 Code A | —28,300 at $0.00 | filing |
| 28 Jan 2022filed 31 Jan 2022 | Gamida Celloption or derivative | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 28 Jan 2022filed 31 Jan 2022 | Gamida Cell | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
News
Israel National Biotech Innovation Center (INBI) launches with Anat Cohen-Dayag as CEO of INBI Corejns.org · 17 Sep 2026
1 headline in the last 90 days name Anat Cohen-Dayag; no company of theirs resolves to a name we track.
Sectors
No trade we could place in a sector.